JP2018030016A - 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断装置 - Google Patents
各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断装置 Download PDFInfo
- Publication number
- JP2018030016A JP2018030016A JP2017213611A JP2017213611A JP2018030016A JP 2018030016 A JP2018030016 A JP 2018030016A JP 2017213611 A JP2017213611 A JP 2017213611A JP 2017213611 A JP2017213611 A JP 2017213611A JP 2018030016 A JP2018030016 A JP 2018030016A
- Authority
- JP
- Japan
- Prior art keywords
- bone
- osteoporosis
- bone tissue
- tissue density
- cavity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 47
- 230000003902 lesion Effects 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000008569 process Effects 0.000 title claims abstract description 4
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 65
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract 2
- 239000011707 mineral Substances 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 17
- 230000037182 bone density Effects 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 3
- 238000000691 measurement method Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000004458 analytical method Methods 0.000 abstract description 16
- 238000003745 diagnosis Methods 0.000 abstract description 11
- 238000005259 measurement Methods 0.000 abstract description 5
- 238000001739 density measurement Methods 0.000 abstract description 4
- 238000002601 radiography Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 208000029725 Metabolic bone disease Diseases 0.000 description 8
- 206010049088 Osteopenia Diseases 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 7
- 238000002405 diagnostic procedure Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 229940070021 anabolic steroids Drugs 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 229960005084 calcitriol Drugs 0.000 description 2
- 235000020964 calcitriol Nutrition 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002436 femur neck Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 235000001892 vitamin D2 Nutrition 0.000 description 2
- 239000011653 vitamin D2 Substances 0.000 description 2
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 229940078581 Bone resorption inhibitor Drugs 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- -1 Calcitonin bisphosphonate Chemical class 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002617 bone density conservation agent Substances 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 125000001153 fluoro group Chemical class F* 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229960000464 oxandrolone Drugs 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000912 stanozolol Drugs 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
- A61B5/4504—Bones
- A61B5/4509—Bone density determination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
- A61B6/505—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for diagnosis of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/02—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material
- G01N23/06—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and measuring the absorption
- G01N23/083—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by transmitting the radiation through the material and measuring the absorption the radiation being X-rays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N9/00—Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity
- G01N9/24—Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity by observing the transmission of wave or particle radiation through the material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N9/00—Investigating density or specific gravity of materials; Analysing materials by determining density or specific gravity
- G01N9/36—Analysing materials by measuring the density or specific gravity, e.g. determining quantity of moisture
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dentistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Optics & Photonics (AREA)
- High Energy & Nuclear Physics (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【解決手段】実験解析方法、組織学的解析方法、放射線学的解析方法(一般的X線検査)を含み、骨組織密度測定装置の使用されるX線吸収法による骨密度の測定には同装置のX線吸収法による海綿骨部における空洞病巣の確定への特殊設定による追加診断基準、つまり、空洞病巣の確定が導入され、骨組織密度測定装置による骨粗鬆症の診断時に検査対象の手足の先の周りには蒸留水が専用クベースに注がれる。
【選択図】図1
Description
・エストロゲン系のホルモン(デビナ、ディビゲル、ディビトレン、エストロフェム、クリメン、クリモノルム、ティボロン等)
・カルシトニン
・ビスホスホネート(アレンドロネート、クロドロナート、アクラスタ等)
・カルシウム剤
・ビタミンD(カルシフェロール、コレカルシフェロール)
・ビタミンDの有効代謝物質(カルシトリオール、アルファカルシドール)
・チアジド系利尿薬
・オセイン・ヒドロキシアパタイ
・アナボリックステロイド(オキサンドロロン、ナンドロロン、スタノゾロール)
・フッ素誘導体(フッ化ナトリウム、モノフルオロりん酸塩)
・アナボリックステロイド
・イプリフラボン類
・オセイン・ハイドロキシアパタイト
・ペプチド(1−34)副甲状腺ホルモン
・プロスタグランジンE2
・成長ホルモン
・パラトルモン
・ビタミンD:コレカルシフェロール(D3)、エルゴカルシフェロール(D2)
・ビタミンDの有効代謝物質:カルシトリオール、アルファドール(オクシデビトム、アルファD3−TEBA)
・カルシウム・ビタミンDの組合せ
第1度オステオペニア:骨組織密度は標準偏差の−1〜−1.5の範囲にある。
第2度オステオペニア:骨組織密度は標準偏差の−1.5〜−2.0の範囲にある。
第3度オステオペニア:骨組織密度は標準偏差の−2.0〜−2.5の範囲にある。
第1度骨粗鬆症:骨組織密度は標準偏差の−2.5以下で、骨折無し
第2度骨粗鬆症:骨組織密度は標準偏差の−2.5以下で、骨粗鬆症性骨折あり
本明細書は、例えば、以下を提供する。
(項目1)
実験解析方法、組織学的解析方法、放射線学的解析方法(一般的X線検査)及びX線吸収測定法による骨密度の測定を含む骨粗鬆症診断法。
(項目2)
診断が骨組織密度測定装置により実施される、項目1に記載の骨粗鬆症診断法。
(項目3)
骨組織密度測定装置には、X線吸収法による海綿骨部における空洞病巣の確定への特殊設定による追加診断基準となる、空洞病巣の確定が導入される、項目1に記載の骨粗鬆症診断法。
(項目4)
骨組織密度測定装置を使い骨粗鬆を診断する際、検査対象である手足の先の周りには蒸留水が専用クベースに注がれる、項目1に記載の骨粗鬆症診断法。
1.特定薬剤の効率性評価のための患者選択条件:空洞病巣ありの患者。
2.骨組織密度が標準偏差の−2.5以下である患者。
3.閉経後等の一次的骨粗鬆症を抱える女性患者か一次的骨粗鬆症を抱える男性患者。
4.系統疾患や内分泌疾患や腫瘍病変に伴う二次的骨粗鬆症を抱える患者が対象外であること。
5.試験に参加する患者は試験参加同意書に署名すること。
6.患者は投与される薬剤を知らないこと(盲試験)。
7.骨X線吸収測定は、両グループを対象に、治療前及び3ヶ月・4ヶ月ごとに実施されること。
得た結果は一般的統計処理の対象であるが、(比較)標準としてはなるべく売れ筋の薬剤が選択されること。
Claims (2)
- X線吸収測定法による骨粗鬆症診断装置であって、
骨密度を測定するための手段と、
軟部組織における過剰塩蓄積を検出するための手段と、
海綿骨部における空洞病巣の存在を検出するための手段と、
治療の効率性を評価するために、骨密度、軟部組織における過剰塩蓄積、および海綿骨部における空洞病巣の過程を監視するための手段と
を含むことを特徴とする骨粗鬆症診断装置。 - 検査の間に蒸留水内に手足を置くための手段をさらに備え、前記置くための手段には、蒸留水が注がれていることを特徴とする、請求項1に記載の骨粗鬆症診断装置。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012115655/14A RU2511430C2 (ru) | 2012-04-19 | 2012-04-19 | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
RU2012115655 | 2012-04-19 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015506934A Division JP2015514499A (ja) | 2012-04-19 | 2012-08-21 | 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018030016A true JP2018030016A (ja) | 2018-03-01 |
Family
ID=49383801
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015506934A Pending JP2015514499A (ja) | 2012-04-19 | 2012-08-21 | 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断法 |
JP2017213611A Pending JP2018030016A (ja) | 2012-04-19 | 2017-11-06 | 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断装置 |
JP2017213612A Active JP6543317B2 (ja) | 2012-04-19 | 2017-11-06 | X線吸収測定法による骨密度の測定による骨保護剤の客観的効率性評価装置 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015506934A Pending JP2015514499A (ja) | 2012-04-19 | 2012-08-21 | 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017213612A Active JP6543317B2 (ja) | 2012-04-19 | 2017-11-06 | X線吸収測定法による骨密度の測定による骨保護剤の客観的効率性評価装置 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20150223770A1 (ja) |
EP (1) | EP2839782A4 (ja) |
JP (3) | JP2015514499A (ja) |
CN (1) | CN104363832A (ja) |
AU (2) | AU2012377477A1 (ja) |
BR (1) | BR112014025994B1 (ja) |
CA (1) | CA2870825C (ja) |
EA (1) | EA027158B1 (ja) |
IL (1) | IL235170B (ja) |
IN (1) | IN2014DN09781A (ja) |
RU (1) | RU2511430C2 (ja) |
UA (1) | UA114626C2 (ja) |
WO (1) | WO2013157983A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2511430C2 (ru) * | 2012-04-19 | 2014-04-10 | Общество С Ограниченной Ответственностью "Парафарм" | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
CN106730122A (zh) * | 2015-01-01 | 2017-05-31 | 何磊 | 一种用于治疗骨质疏松的治疗仪 |
RU2607304C1 (ru) * | 2015-11-23 | 2017-01-10 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" (НИИ КПССЗ) | Способ прогнозирования годовой антиостеопоротической эффективности менопаузальной гормональной терапии |
CN108538393B (zh) * | 2018-04-02 | 2021-12-10 | 重庆邮电大学 | 基于大数据的骨质质量评估专家系统及预测模型建立方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09122107A (ja) * | 1995-11-02 | 1997-05-13 | Teijin Ltd | 骨計測方法 |
JPH09327462A (ja) * | 1996-06-10 | 1997-12-22 | Asuka B F Kk | 骨評価装置用の踵骨部測定体 |
JP2008514368A (ja) * | 2004-09-30 | 2008-05-08 | ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア | 特性判定方法、記録装置、評価方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0775606B2 (ja) * | 1993-06-30 | 1995-08-16 | アロカ株式会社 | 生体組織診断装置 |
JP3499761B2 (ja) * | 1998-10-22 | 2004-02-23 | 帝人株式会社 | 骨画像処理方法及び骨強度評価方法 |
US6430427B1 (en) * | 1999-02-25 | 2002-08-06 | Electronics And Telecommunications Research Institute | Method for obtaining trabecular index using trabecular pattern and method for estimating bone mineral density using trabecular indices |
US6285901B1 (en) * | 1999-08-25 | 2001-09-04 | Echo Medical Systems, L.L.C. | Quantitative magnetic resonance method and apparatus for bone analysis |
RU2159577C1 (ru) * | 2000-04-11 | 2000-11-27 | Михайлов Марс Константинович | Способ определения содержания минерального вещества в костной ткани |
US8639009B2 (en) * | 2000-10-11 | 2014-01-28 | Imatx, Inc. | Methods and devices for evaluating and treating a bone condition based on x-ray image analysis |
AU1319302A (en) * | 2000-10-11 | 2002-04-22 | Osteonet Com Inc | Methods and devices for analysis of x-ray images |
US6975894B2 (en) * | 2001-04-12 | 2005-12-13 | Trustees Of The University Of Pennsylvania | Digital topological analysis of trabecular bone MR images and prediction of osteoporosis fractures |
AU2002360478A1 (en) * | 2001-12-05 | 2003-06-17 | The Trustees Of The University Of Pennsylvania | Virtual bone biopsy |
US20050015002A1 (en) * | 2003-07-18 | 2005-01-20 | Dixon Gary S. | Integrated protocol for diagnosis, treatment, and prevention of bone mass degradation |
JP2005034539A (ja) * | 2003-07-18 | 2005-02-10 | Ibaraki Prefecture | 骨密度分布測定機能付きx線画像診断装置 |
US8085898B2 (en) * | 2009-05-08 | 2011-12-27 | Osteometer Meditech, Inc. | Apparatus for bone density assessment and monitoring |
RU2305491C2 (ru) * | 2003-12-05 | 2007-09-10 | Российская медицинская академия последипломного образования Министерства здравоохранения Российской Федерации (РМАПО МЗ РФ) | Способ исследования и диагностики патологии костной ткани при сахарном диабете |
JP2008530227A (ja) * | 2005-02-16 | 2008-08-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 骨状態を治療または予防する薬剤組成物 |
JP2008206560A (ja) * | 2007-02-23 | 2008-09-11 | Kyushu Univ | 骨塩量測定装置 |
US8679019B2 (en) * | 2007-12-03 | 2014-03-25 | Bone Index Finland Oy | Method for measuring of thicknesses of materials using an ultrasound technique |
RU2412650C1 (ru) * | 2009-06-01 | 2011-02-27 | Закрытое Акционерное Общество "Рентгенпром" (Зао "Рентгенпром") | Способ определения величин минеральной и объемной плотности костной ткани, относящийся к одноэнергетической рентгеновской денситометрии |
JP5537346B2 (ja) * | 2010-09-06 | 2014-07-02 | 株式会社日立メディコ | 画像診断支援装置、画像診断支援方法 |
RU2511430C2 (ru) * | 2012-04-19 | 2014-04-10 | Общество С Ограниченной Ответственностью "Парафарм" | Способ диагностики остеопороза, методом определения динамики закрытия полостных образований для оценки эффективности применения различных остеопротекторов |
-
2012
- 2012-04-19 RU RU2012115655/14A patent/RU2511430C2/ru active
- 2012-08-21 BR BR112014025994-1A patent/BR112014025994B1/pt active IP Right Grant
- 2012-08-21 US US14/395,480 patent/US20150223770A1/en active Pending
- 2012-08-21 CA CA2870825A patent/CA2870825C/en active Active
- 2012-08-21 CN CN201280074013.2A patent/CN104363832A/zh active Pending
- 2012-08-21 EP EP12874860.5A patent/EP2839782A4/en not_active Ceased
- 2012-08-21 AU AU2012377477A patent/AU2012377477A1/en not_active Abandoned
- 2012-08-21 EA EA201401156A patent/EA027158B1/ru active IP Right Revival
- 2012-08-21 JP JP2015506934A patent/JP2015514499A/ja active Pending
- 2012-08-21 UA UAA201412407A patent/UA114626C2/uk unknown
- 2012-08-21 WO PCT/RU2012/000688 patent/WO2013157983A1/ru active Application Filing
-
2014
- 2014-10-19 IL IL235170A patent/IL235170B/en active IP Right Grant
- 2014-11-19 IN IN9781DEN2014 patent/IN2014DN09781A/en unknown
-
2017
- 2017-09-19 AU AU2017232044A patent/AU2017232044B2/en active Active
- 2017-11-06 JP JP2017213611A patent/JP2018030016A/ja active Pending
- 2017-11-06 JP JP2017213612A patent/JP6543317B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09122107A (ja) * | 1995-11-02 | 1997-05-13 | Teijin Ltd | 骨計測方法 |
JPH09327462A (ja) * | 1996-06-10 | 1997-12-22 | Asuka B F Kk | 骨評価装置用の踵骨部測定体 |
JP2008514368A (ja) * | 2004-09-30 | 2008-05-08 | ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア | 特性判定方法、記録装置、評価方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104363832A (zh) | 2015-02-18 |
BR112014025994A2 (pt) | 2017-06-27 |
AU2017232044A1 (en) | 2017-10-12 |
UA114626C2 (uk) | 2017-07-10 |
RU2511430C2 (ru) | 2014-04-10 |
EA201401156A1 (ru) | 2015-05-29 |
WO2013157983A1 (ru) | 2013-10-24 |
JP2018030017A (ja) | 2018-03-01 |
IL235170B (en) | 2021-06-30 |
RU2012115655A (ru) | 2013-10-27 |
CA2870825A1 (en) | 2013-10-24 |
BR112014025994B1 (pt) | 2022-05-17 |
AU2017232044B2 (en) | 2019-05-16 |
EA027158B1 (ru) | 2017-06-30 |
JP6543317B2 (ja) | 2019-07-10 |
EP2839782A4 (en) | 2016-01-06 |
JP2015514499A (ja) | 2015-05-21 |
AU2012377477A1 (en) | 2014-12-11 |
CA2870825C (en) | 2023-09-26 |
US20150223770A1 (en) | 2015-08-13 |
IL235170A0 (en) | 2014-12-31 |
EP2839782A1 (en) | 2015-02-25 |
IN2014DN09781A (ja) | 2015-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zysset et al. | Clinical use of quantitative computed tomography–based finite element analysis of the hip and spine in the management of osteoporosis in adults: the 2015 ISCD official positions—part II | |
Lee et al. | Phantomless calibration of CT scans for measurement of BMD and bone strength—inter-operator reanalysis precision | |
Adams et al. | Quantitative computer tomography in children and adolescents: the 2013 ISCD Pediatric Official Positions | |
Engelke et al. | Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions | |
Krieg et al. | Effects of anti-resorptive agents on trabecular bone score (TBS) in older women | |
JP2018030016A (ja) | 各種骨保護剤効率性評価用の空洞病巣補填過程確認法による骨粗鬆症診断装置 | |
Deng et al. | Differences in bone mineral density, bone mineral content, and bone areal size in fracturing and non-fracturing women, and their interrelationships at the spine and hip | |
Engelke et al. | Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA) | |
Ito et al. | Analysis of hip geometry by clinical CT for the assessment of hip fracture risk in elderly Japanese women | |
Rinaldi et al. | Peripheral quantitative computed tomography: optimization of reproducibility measures of bone density, geometry, and strength at the radius and tibia | |
Crabtree et al. | Bone densitometry: current status and future perspective | |
Davis et al. | Predictors of femoral neck fracture following hip resurfacing: a cadaveric study | |
Kullenberg | Reference database for dual X-ray and laser Calscan bone densitometer | |
Tarantino et al. | Hip fractures in the elderly: the role of cortical bone | |
Bergot et al. | The degree and distribution of cortical bone mineralization in the human femoral shaft change with age and sex in a microradiographic study | |
Gutekunst et al. | Impact of Charcot neuroarthropathy on metatarsal bone mineral density and geometric strength indices | |
Kamer et al. | Bone mass distribution of the distal tibia in normal, osteopenic, and osteoporotic conditions: an ex vivo assessment using HR-pQCT, DXA, and computational modelling | |
Schmidutz et al. | Cortical bone thickness predicts the quantitative bone mineral density of the proximal humerus | |
Du et al. | Quantitative ultrasound measurements of bone quality in female adolescents with idiopathic scoliosis compared to normal controls | |
Glüer | Quantitative computed tomography in children and adults | |
Rianon et al. | Fracture risk assessment in older adults using a combination of selected quantitative computed tomography bone measures: a subanalysis of the Age, Gene/Environment Susceptibility-Reykjavik Study | |
Guglielmi et al. | Three-year prospective study on fracture risk in postmenopausal women by quantitative ultrasound at the phalanges | |
Sherk et al. | Age and sex differences in estimated tibia strength: influence of measurement site | |
RU2567277C2 (ru) | Способ оценки состояния слезоотводящих путей | |
Guglielmi et al. | Bone densitometry: current status and future trends |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171117 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20181030 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190607 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191203 |